A new clinical trial gives providers objective, measured evidence on DAO Botox® injection technique and its effect on lower-face muscle balance. The findings show why new injectors need to think beyond the patient’s stated concern to guide both the treatment and the result.
June’s clinical evidence points to a more disciplined approach to combination care: select and sequence treatment based on anatomy, evidence quality, recovery burden, and the patient’s changing trajectory. This update examines new data on skin-quality injectables, radiofrequency microneedling, and regenerative approaches to help aesthetic providers build safer, more individualized plans.
The most qualified patient who walks into an aesthetic practice is usually one sent by another provider — someone who already trusts the recommendation before they call to book. Building those relationships requires deliberate outreach, not just doing good work and waiting.
Obagi® saypha® ChIQ™ is the latest FDA-approved HA filler for cheek augmentation, but entry into a crowded midface filler market demands a rigorous evaluation framework. This article walks through the clinical questions every injector should ask before adding a new product.
Burnout in insurance-based medicine isn’t new — but what physicians are doing about it is changing. Providers from emergency medicine, urology, OB/GYN, family medicine, and beyond are adding aesthetic medicine as a cash-pay, patient-driven complement to their existing practice.
The May 2026 aesthetic medicine update covers a neurotoxin pipeline producing genuinely new options and a patient population that is outgrowing the standard consult model. Providers who act on this month’s clinical and business signals — from GLP-1 protocol updates to the growing male aesthetic market — will be better positioned heading into the second half of 2026.
April’s clinical and business signals point in the same direction: the practices growing most consistently right now are those expanding their definition of who their patient is. From menopausal skin protocols to GLP-1 consult frameworks and wellness integration strategies, this month’s update covers what to implement now and what to keep on your radar.
A recombinant botulinum toxin type A called YY001 recently completed a Phase III trial showing favorable efficacy and safety results compared to onabotulinumtoxinA for glabellar lines. While the product is not available in the United States, understanding how recombinant toxins differ from traditional formulations helps aesthetic providers evaluate emerging data and marketing claims.
Patients are already asking about the salmon facial. Here’s what the clinical evidence shows, why the U.S. entry point is lower than most providers expect, and how to evaluate it as a revenue opportunity for your practice.
Relfydess (relabotulinumtoxinA) is a ready-to-use, complex-free liquid neurotoxin with Phase 3 data supporting rapid onset and sustained improvement for glabellar lines and crow’s feet in many patients. Here’s what aesthetic providers need to know about its clinical profile—and how to prepare their practice before adding it to the menu.